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Abstract: Neurotrophins (NTs) belong to a family of structurally and functionally related proteins, they are the subsets of 
neurotrophic factors. Neurotrophins are responsible for diverse actions in the developing peripheral and central nervous 
systems. They are important regulators of neuronal function, affecting neuronal survival and growth. They are able   
to regulate cell death and survival in development as well as in pathophysiologic states. NTs and their receptors are  
expressed in areas of the brain that undergo plasticity, indicating that they are able to modulate synaptic plasticity. 
Recently, neurotrophins have been shown to play significant roles in the development and transmission of neuropathic 
pain. Neuropathic pain is initiated by a primary lesion or dysfunction in the nervous system. It has a huge impact on  
the quality of life. It is debilitating and often has an associated degree of depression that contributes to decreasing human well 
being. Neuropathic pain ranks at the first place for sanitary costs.  
Neuropathic pain treatment is extremely difficult. Several molecular pathways are involved, making it a very complex  
disease. Excitatory or inhibitory pathways controlling neuropathic pain development show altered gene expression, caused 
by peripheral nerve injury. At present there are no valid treatments over time and neuropathic pain can be classified as an 
incurable disease. 
Nowadays, pain research is directing towards new molecular methods. By targeting neurotrophin molecules it may be 
possible to provide better pain control than currently available.  
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NEUROTROPHINS: OVERVIEW 
  The neurotrophins (NTs) nerve growth factor (NGF), 
brain-derived neurotrophic factor (BDNF), neurotrophin-3 
(NT-3) and neurotrophin-4 (NT-4) belong to a family of 
structurally and functionally related proteins and are a subset 
of neurotrophic factors. NTs are responsible for diverse ac-
tions in the developing peripheral and central nervous sys-
tems [1]. Indeed, NTs, once released by target cells, regulate 
the type and the number of afferent synapses by promoting 
the survival of discrete neuronal sub populations [2]. They are 
the important regulators of neuronal functions, affecting neu-
ronal survival and growth, regulating differentiation, influ-
encing cell fate choices and regulating neurite morphology. 
They are also able to regulate cell death and survival in   
development as well as pathophysiologic states. NTs and 
their receptors are expressed in areas of the brain that   
undergo plasticity, indicating that they are able to modulate 
synaptic plasticity. Rapid NT-mediated responses, such as 
changes in synaptic activity, probably result partly from the 
activation of second messengers and/or kinases that in turn 
affects ion channel function, neuro-transmitter release, and/or 
synaptic structure. Slow NT-mediated responses, such as 
NT-induced differentiation, depend on new gene expression 
[3]. Mature NTs are homodimeric proteins derived by   
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proteolytic cleavage of precursor proteins encoded by differ-
ent genes. NTs interact with two categories of cell surface 
receptors mediating neurotrophin actions: the Trk family 
(TrkA, TrkB and TrkC) of high affinity tyrosine kinase re-
ceptors and the low-affinity p75 neurotrophin receptor 
(p75NTR). TrkA (also known as neurotrophic tyrosine 
kinase receptor, type 1 [NTRK1]) is the high-affinity recep-
tor for NGF; while for BDNF and NT-4, it is TrkB; for NT-
3, it is TrkC [4, 5]. All members of NT family are able to 
activate the p75 receptor. Through the activation of these 
receptors, NTs activate many intracellular signalling path-
ways. For example, NGF binds and dimerizes its receptor 
TrkA; dimerization activates the receptor's intrinsic tyrosine 
kinase. Activated TrkA autophosphorylates several tyrosine 
residues present in the receptor's cytoplasmic domain. The 
phosphotyrosines serve as docking sites for adapter proteins 
and kinases such as phospholipase C (PLC), phosphatidy-
linositol-3 kinase (PI3K), and the adapter protein src homol-
ogy-2 containing (SHC) [6]. These molecules are able to 
trigger multiple kinase bio-chemical cascades that culminate 
in the phosphorylation and activation of several transcription 
factors (i.e. Ras/Raf, the Cdc42/Rac/RhoG protein family, 
mitogen- and extracellular-regulated kinase (MEK), mitogen-
activated protein kinase (MAPK), extracellular-regulated 
kinase [ERK]), which in turn induce direct gene expression 
[7]. NGF and BDNF are able to activate cyclic AMP   
response element-binding protein (CREB) by a calcium/ 
calmodulin-dependent kinase IV (CaMKIV)-regulated path-
way [8], suggesting that CREB could play a central role in 
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  Several neurodegenerative diseases and psychiatric dis-
orders, such as Alzheimer's disease, Parkinson's disease, 
depression and substance abuse are associated with NT dys-
regulation [9]. Recently, NTs have been shown to be in-
volved in the neuronal mechanism underlying neuropathic 
pain development and transmission. Due to their important 
role in this syndrome, NTs could represent a neuropathic 
pain pharmacological target for the next future of pain-
medicine. 
NEUROPATHIC PAIN: PHYSIOLOGY AND CLASSI-
CAL PHARMACOLOGICAL TREATMENT 
  Neuropathic pain can occur secondarily to injury of the 
central nervous system, but it occurs most commonly in as-
sociation with a primary lesion or dysfunction to the periph-
eral nervous system [10, 11]. These injuries can be iatrogenic 
(amputations, cholecistectomy, mastectomy, dental avulsion), 
or can be due to trauma, tumour compressing peripheral 
nerves, toxins used for chemotherapy, metabolic (diabetes) 
and viral diseases (Herpes Zoster), nerve compression and 
inflammation following disc herniation. 
  Neuropathic pain is often associated with a continuous 
burning condition, accompanied by abnormal sensory symp-
toms, such as hyperalgesia (an increased response to a stimu-
lus which is normally painful; patients with hyperalgesia 
perceive pain spontaneously) and allodynia (pain as a result 
of a stimulus which does not provoke pain; patients with 
allodynia do not feel constant pain; indeed in the absence  
of a stimulus there is no pain) [12]. Central mechanisms   
controling such spread of pain, arise from neurochemical   
and functional changes, and therefore, neuropathic pain 
should be considered a neuropathological condition [13]. 
  Dorsal horn spinal cord is the first CNS-area involved in 
the pain control and processing. Nociceptive and non-
nociceptive afferent pathway converge in this site, is that   
the specific neurons transmit nociceptive information to 
higher centres in the brain. Moreover, nociceptive neurons 
located in the superficial Lamina I (marginal layer) and in 
the Lamina II (substantia gelatinosa) and receiving direct 
synaptic input from A-delta fibers, together with indirect input 
from C-fibers via neurons in Lamina II, project nociceptive 
signaling to higher brain centres [14]. 
  Central anatomical and biochemical modifications follow 
peripheral nerve lesions: central sensitization, supra-spinal, 
spinal re-organization and changes in the inhibitory path-
ways. Primary afferent neurons and the sympathetic neuron 
sproutings are the most important peripheral modifications 
[15]. Neurotrophic factors and several cytokines, such as 
interleukin-1 (IL-1) and tumour necrosis factor-alpha (TNF-
alpha), can be responsible for the sprouting formation [14, 
16]. Other modifications are: nociceptor sensitization, altera-
tions in ion channel expression, ectopic and spontaneous 
discharge [14]. This latter alteration is a massive increase in 
the level of normal firing, following nerve injury of the af-
ferent neurons and it occurs close to the site of the injury. 
Probably, after the nerve injury, an altered gene expression 
of the voltage-gated sodium channels causes an increased 
firing and, in turn, sensitization of peripheral nociceptors 
[17]. Neurotrophin, in particular NGF, may participate in this  
altered gene expression [18]. 
  Neuropathic pain is associated with hyperactivity of exci-
tatory (glutamatergic) transmission and hypoactivity of the 
inhibitory (GABAergic) transmission. GABA and glutamate 
are the key neurotransmitters involved in the neuropathic 
pain pathways [19]. Glutamate released by C-fibers leads to 
an increasingly enhanced response of the dorsal horn neu-
rons: this phenomenon of central sensitization is called 
“wind-up” [20]. As for GABA, it is known that increasing its 
neurotransmission in the brain insular cortex enhances the 
anti-nociceptive response. GABAergic neurons control the 
projections modulating the nociceptive responses: the 
noradrenergic bulbo-spinal projections from the insular cor-
tex to the locus coeruleus and the projections from cortex to 
amygdala [21]. 
  The neuropathic pain syndrome is also responsible for 
changes in DNA expression. After peripheral nerve damage, 
the apoptotic genes mRNA expression levels of the bcl-2 cell 
death-associated family in the lumbar dorsal horn of the spi-
nal cord of neuropathic rats are modified [13, 22]. 
  Tricyclic antidepressant and/or anticonvulsant drugs are 
the current available treatments for neuropathic pain, what-
ever its origin. All these treatments, however, even when 
well used, provide a long lasting relief only in a limited per-
centage of patients (30%, e.g. comparable to placebo), before 
pain reappearing. Classical pharmacological treatment of 
neuropathic pain includes: lidocaine, lamotrigine, aceta-
minophen, dextromethorphan, carbamazepine, gabapentin, 
valproic acid, opioid analgesics and tramadol hydrochloride. 
Only 40-60% of patients achieve partial relief [23]. The di-
versity of therapeutic approaches sharing an equal percent-
age of failure suggests that each of them targets only a few 
of the multiple pathological changes observed during the 
development of the disease. The overall approach to neuro-
pathic pain is partial and palliative, i.e. it targets the epiphe-
nomenon but not the cause. 
NEUROTROPHINS IN NEUROPATHIC PAIN 
Nerve Growth Factor 
  Increased emerging studies, highlighted key roles of 
NGF in neuropathic pain conditions [24-29], although   
originally discovered as a trophic factor for sympathetic and 
sensory neurons during its development.  
  NGF acts as a pathogenic pain mediator [30, 31]. Its lev-
els are elevated in several painful conditions and its admini-
stration in rats or for that matter in humans results in pro-
nounced mechanical and thermal hyperalgesia [32, 33].  
  The increase in the level of normal firing in the afferent 
neurons after nerve injury is due to an altered expression of 
several types of sodium channels, such as the voltage-gated 
sodium channels [17]. The mechanisms responsible for the 
changes in the channel expression are not yet known, but NT 
supply can be involved [14]. Indeed, NGF is able to up-
regulate the voltage gated sodium channels expression in 
neuropathic pain states, that it is critically linked to sensitiza-
tion of peripheral nociceptors [34]. 
  More recently, in the chronic constriction injury (CCI) 
model of peripheral neuropathy in rat, it has been demon-
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ganglia (DRG), in the spinal cord and in the periaqueductal 
grey matter (PAG). Systematic treatment with the anti-
hyperalgesic and neuroregenerative compound acetyl-l-
carnitine (ALCAR) was able to normalize NGF levels [35]. 
In addition, the NGF expression is increased in the red   
nucleus of the brain of neuropathic rats [36], as well as in 
DRG of rat pups during postnatal life after complete Freund's 
adjuvant (CFA)-induced peripheral inflammation [37]. 
  One of the proposed mechanisms of action of NGF might 
through up-regulated several pain-related genes in the   
primary sensory neurons of DRG. Indeed, genes codifying 
for substance P, calcitonin gene-related peptide, TRPV1, 
Na(v)1.8 and Na(v)1.9 sodium channels and mu opioid re-
ceptor (MOR) are up-regulated by NGF [38-41]. 
  In addition, the pain-activated glia are important sources 
of NGF [42]. In the neuropathic pain model obtained by   
peripheral axotomy, the initial NGF levels decline, due to  
disruption of transport from target tissues. NGF levels then 
rebound, as satellite glial cells begin to synthesize NGF and 
supply it to the neurons. Indeed, NGF and NT-3 synthesis  
are up-regulated in the satellite cells surrounding neurons in  
lesioned DRG as early as 48h after a nerve injury, indicating 
that the satellite cell-derived NTs are involved in the   
induction of sympathetic sprouting following peripheral 
nerve injury [43]. 
  NGF plays a key role also in post-operative pain. Surgi-
cal trauma induce changes in the central nervous system pain 
modulating mechanisms. A Post-operative pain can trigger 
the central sensitization of the spinal cord and, in turn, can 
develop into a chronic neuropathic pain. NGF is released in 
incised tissue and contributes to hyperalgesia in incisional 
pain. NGF mRNA is increased and the large-molecular-
weight form of NGF protein is expressed in the region   
adjacent to the incision at the plantar aspect of hind paw in 
rat [44]. 
  Recent research is moving to target NGF-mediated pain. 
Interesting, drugs blocking NGF are proving to be effective 
in animal models of pain in which the non-steroid anti-
inflammatory drugs (NSAIDs) and opiates have no effect in 
pain relief [45]. The development of humanized monoclonal 
antibodies to NGF or its TrkA receptor, and the sequestration 
of NGF using TrkA domain 5 (TrkAd5), a soluble receptor 
protein that binds NGF with picomolar affinity seem to be 
effective in a number of preclinical models of pain [46]. Tar-
geting either the extracellular NGF binding domain of TrkA 
or probably its intracellular tyrosine kinase domain with 
small-molecule TrkA antagonists that can be the next step in 
the antibody-based therapy. In fact, the anti-NGF treatment 
was able to reduce neuropeptide levels and the nociceptive 
sensitization in rats with complex regional pain syndrome 
type I. According to the authors, anti-NGF antibodies pre-
vented mechanical nociceptive sensitization, reduced spinal 
cord dorsal horn Fos expression and the sciatic nerve neu-
ropeptide content [47]. The anti-NGF antibodies used in this 
study were the TrkA-immunoglobulin G (TrkA-IGG) fusion 
proteins able to bind NGF, thus blocking the binding of NGF 
to the TrkA and p75-NGF receptors and inhibiting TrkA 
autophosphorylation [48]. Anti-NGF antibodies were able to 
reverse the tactile allodynia and thermal hyperalgesia in the 
complete Freund's adjuvant-induced hind-paw inflammation, 
spinal nerve ligation, chronic constriction injury and strepto-
zotocin-induced neuropathic pain models in rats and mice 
[28]. In addition, TrkA receptor also represents a suitable 
target for the antibody-based drugs. The anti-TrkA mono-
clonal antibody MNAC13 has been shown to posses a sig-
nificant anti-allodynic effect on neuropathic pain, inducing 
functional recovery in mice subjected to sciatic nerve   
ligation [49]. Interestingly, the molecular strategies directed 
to blocking Trka-mediated events are showing promising 
results. An intrathecal administration a of antisense oligode-
oxynucleotides to TrkA was able to decrease burn-induced 
primary mechanical hyperalgesia in dose-related manner in 
the rat [50]. A non-peptidic molecule, ALE-0540, inhibits 
the binding of NGF to TrkA, and, of course, signal transduc-
tion and biological responses mediated by TrkA receptors. 
Administration of ALE-0540 in rats decreased allodynia in 
the L5/L6 ligation model of neuropathic pain [51]. Given 
that studies, NGF blockers could be a new option for the 
next generation in neuropathic pain drugs. 
  On the other hand, NGF may produce beneficial effects 
in neuropathic pain. It has been demonstrated that NGF 
could be effective in restoring homeostatic conditions in the 
spinal cord and maintaining analgesia in neuropathic pain 
animals. Intrathecal NGF administration reduced allodynia, 
thermal hyperalgesia, reversed neuro-glial morphological 
and the molecular changes occurring in neuropathic animals. 
Moreover, as an NGF-mimetic peptide was shown to reduce 
neuropathic behaviour and restore neuronal function in a rat 
model of peripheral neuropathic pain [52, 53]. In a phase-II 
trial, it has been found a positive effect of recombinant hu-
man
  NGF on neuropathic pain in HIV-associated sensory 
neuropathy, even if injection site hyperalgesia was frequent 
[54]. 
  Taken together these studies suggest that NGF is once of 
the major mediators of neuropathic pain, indicating a new 
therapeutic target for pain relief. 
BRAIN-DERIVED NEUROTROPHIC FACTOR 
  BDNF shows similar hyperalgesic effects to NGF [35]. 
BDNF is involved in the central sensitization and synaptic 
plasticity in the spinal cord. It has been shown to contribute 
to the development and maintenance of neuropathic pain by 
activation of the dorsal horn NR2B-containing NMDA 
(NMDA-2B) receptors [55]. Indeed, in the spinal nerve   
ligation (SNL) model of neuropathic pain, BDNF expression 
is significantly up-regulated in the spinal dorsal horn in   
SNL rats. The maximal enhancement of BDNF expression  
occurred in an early stage (24-48h) after SNL, indicating that 
BDNF/TrkB-mediated signalling pathway within the spinal 
cord could be involved in the induction of neuropathic pain 
in early stage after nerve injury. BDNF expression is also 
significantly up-regulated in DRG sensory neurons in lumbar 
5 ventral root transection model of neuropathic pain [56]. 
These data highlight that an increased BDNF expression in 
DRG primary sensory neurons and spinal cord dorsal horn 
can be an important factor in the induction of neuropathic 
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can be anterogradely transported to the central terminals of 
the primary afferents in the spinal dorsal horn, enhanced its 
local expression [26].  
  It has been demonstrated that the oral administration of  
protein kinase inhibitor, protein phosphatase 1 (1NM-PP1),  
is at doses that blocked phosphorylation of TrkB in the   
spinal cord and is able to prevent the development of tissue-  
or nerve injury-induced heat and the mechanical hyper- 
sensitivity in mice, indicating that TrkB signalling is not   
only an important contributor to the induction of heat   
and mechanical hypersensitivity produced by tissue or   
nerve injury but also to the development and persistence of  
neuropathic pain [57, 58]. 
  BDNF is strongly involved in the axonal sprouting of 
intraspinal serotonergic fibers following the dorsal root inju-
ries (DRIs). This model of neuropathic pain results in the 
permanent disconnection of nerve roots from the spinal cord 
and leads to the sensory impairments, loss of sensation and 
axonal sprouting of intraspinal serotonergic fibers. Endoge-
nous BDNF is required for this sprouting of serotonergic 
axons. Its upregulation is mediated by activated microglia 
[59]. Besides serotoninergic sprouting, peripheral nerve   
injury also results in sprouting of the spinal noradrenergic 
fibers in rodent dorsal horn lumbar spinal cord [60]. BDNF 
modulates the noradrenergic system; indeed, spinal nor- 
adrenergic fibers were found increased in L4-L6 DRG   
ipsilateral to injury and in lumbar spinal cord following 
nerve injury. After intrathecal infusion of BDNF antiserum 
spinal noradrenergic sprouting was prevented. Authors   
suggest that increased BDNF synthesis and release drive the 
spinal noradrenergic sprouting following nerve injury, and 
that this sprouting may paradoxically increase the capacity 
for analgesia in neuropathic pain [60]. 
  One of the proposed mechanisms of action of BDNF in 
neuropathic pain can be through enhanced neuronal sensitiv-
ity to painful stimuli and an increased co-expression of 
thermo-TRP channels. Indeed, it has been demonstrated that 
BDNF is able to regulate the pattern of expression and the 
level of activity of the transducer channel TRPV1 [61]. A 
well-known receptor that has been implicated in the   
mechanical, chemical and thermal nociceptive stimuli trans-
mission. It is noteworthy that TRPV1 is also regulated   
by NGF [62]. Another possible mechanism concerns the 
involvement of microglia in the pain development. In fact, in 
response to the peripheral nerve injury, the spinal cord acti-
vated microglia P2X(4) receptors (P2X(4)R) are over-
expressed. Activated P2X(4)R leads to the release of BDNF 
from microglia [63, 64]. 
  As for NGF, an antibody-based therapy is showing good 
results for targeting BDNF. Indeed, anti-BDNF antibodies 
were able to postpone the mechanical hyper-nociception in 
mice with brachial plexus avulsion pain model [65]. A   
repeated intrathecal pre-treatment with specific anti- 
BDNF antibodies was able to abolish thermal hyperalgesia 
induced by nerve ligation in mice. Additionally, the thermal 
hyperalgesia was completely suppressed by a repeated   
intrathecal injection of specific antibody to its full-length 
TrkB [58]. 
  The BDNF also has another side. Indeed, recombinant 
adeno-associated viral vector-mediated over-expression of 
BDNF has reversed the pain-like behaviours in neuropathic 
rats, suggesting that by changing the levels of neurotrophins 
in the spinal cord micro-environment following nerve injury, 
it is possible to recover normal function [66]. 
NEUROTROPHIN-3 
  Neurotrophin-3 has been shown to have antagonistic ef-
fects to NGF in the pain processing, through negative modu-
lation of NGF receptor expression and associated nociceptive 
phenotype in intacted neurons [14]. It has been demonstrated 
that NT-3 reduces an over-expression of Na(v)1.8 and 
Na(v)1.9 channels in DRG neurons of the neuropathic rats 
[34]. As mentioned above, the NT-3 is able to interact with 
the TrkC receptor, but it also possesses the ability to signal 
via  a TrkA receptor. NT-3 could act on Na(v)1.8 and 
Na(v)1.9 channel of expression. Interestingly, NT-3 is able 
to cause tyrosine-phosphorylation of the glial cell line-
derived neurotrophic factor (GDNF)/Ret receptor and activa-
tion of PI3-kinase/Akt pathway [67]. In addition, NT-3 is 
able to reverse the CCI-induced thermal hyperalgesia through 
a down-regulation of TRPV1 receptor expression [68]. 
  Moreover, the NT-3 is able to downregulate the potas-
sium Kv channel of gene expression in DRG neurons follow-
ing the nerve injury [69].  
  The role played by NT-3 in neuropathic pain is still less 
clear. It has been proposed that NT-3 can be involved in a 
long-term change of neuronal excitability. Indeed, it has 
been proved that NT-3 to promotes an extensive growth of 
lesioned axons in rat crushed dorsal columns [70]. 
  Neurotrophic factor delivered by an adenovirus-based 
gene therapy can be a promising strategy for the prevention 
of neuropathic pain [71]. Recombinant adenovirus encoding 
NT-3 intramuscular injected in rats with streptozotocin-
induced diabetes has decreased the denervation observed in 
this model of diabetic neuropathy [72].  
  Taken together these findings are consistent with an   
analgesic role for NT-3. Conversely, the NT-3 other side: 
intrathecal administration of NT-3 antisense oligonucleotides 
attenuates nerve injury-induced sprouting and allodynia   
[73]. 
NEUROTROPHIN-4 
  It is not yet clear the role played by NT-4 in neuropathic 
pain physiology. NT-4 is synthesized by DRG and expressed 
in the rat spinal cord [58]. It is a ligand of the TrkB tyrosine 
kinase receptor, but it mediates to diverse effects in relation 
to BDNF [74]. It has also been demonstrated that repeated 
injections of a specific antibody to NT-4 failed to reverse the 
thermal hyperalgesia caused by sciatic nerve ligation in mice 
[58]. These results indicate that NT-4 can be an essential 
component of nociceptive processing. However, its use in 
the pharmacological treatment can be suitable. Indeed, the 
addition of NT-4 to injured nerves improves their regenera-
tion potential and can affect axon guidance [75]. In addition, 
NT-4 drives peripheral nerve regeneration through regulation 
of the expression of myelin-associated glycoprotein, myelins Role of Neurotrophins in Neuropathic Pain  Current Neuropharmacology, 2011, Vol. 9, No. 4    527 
basic protein, and low-molecular-weight neurofilament   
protein [76]. However, further studies are needed to better 
elucidate the role of NT-4 in a neuropathic pain. 
CONCLUSIONS 
  Neuropathic pain is a very complex disease, involving 
several molecular pathways. Due to its individual character, 
the treatment is extremely difficult. The current available 
drugs have a generalized nature and act only on the temporal 
pain symptoms rather than being targeted towards the several 
mechanisms underlying the generation and propagation of 
pain. Despite over fifty years of research there been no valid 
treatments over time and the neuropathic pain can be classi-
fied as an incurable disease without treatment. The increas-
ing number of negative clinical trials of pharmacological 
treatments for neuropathic pain highlights the need for new 
molecular targets. NTs represent new promising potential 
targets for the next-future drugs for neuropathic pain relief.  
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